Conjugated estrogens for the management of gastrointestinal bleeding secondary to uremia of acute renal failure

Pharmacotherapy

Volumn 18, Issue 1, 1998, Pages 210-217

  Heunisch, Carol ^a   Resnick, Daniel J ^b   Vitello, Joseph M ^b   Martin, Steven J ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; DESMOPRESSIN; OCTREOTIDE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLEEDING; BLEEDING TIME; CASE REPORT; CRYOPRECIPITATE; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HEMOSTASIS; HUMAN; MALE; THROMBOCYTE DYSFUNCTION; UREMIA;

ESTROGENS, CONJUGATED (USP); FATAL OUTCOME; GASTROINTESTINAL HEMORRHAGE; HEMOSTATICS; HUMANS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; UREMIA;

EID: 0031975664     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Remuzzi G. Bleeding disorders in uremia: pathophysiology and treatment. Adv Nephrol 1989;18:171-86.
2. Jubelirer S. Hemostatic abnormalities in renal disease. Am J Kidney Dis 1985;5(5):219-25.
3. Couch P, Stumpf JL. Management of uremic bleeding. Clin Pharm 1990;9:673-81.
4. Remuzzi G. Bleeding in renal failure. Lancet 1988;1:1205-8.
5. Fenton JW, Ofosu FA, Brezniak DV, et al. Understanding thrombosis and hemostasis. Hematol Oncol Clin North Am 1993;7:1107-19.
6. Eschbach JW, Adamson JW. Hematologic consequences of renal failure. In: Brenner BM, Rector FC, eds. The kidney. Philadelphia: WB Saunders, 1991:2019-30.
7. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12.
8. Watson AJ, Keogh JAB. 1-Deamino-8-d-arginine vasopressin (DDAVP): a potential new treatment for the bleeding diathesis of acute renal failure. Pharmacotherapeutica 1984;3(9): 618-22.
9. Mosdell KW, Visconti JA. Emerging indications for octreotide therapy. 1. Am J Hosp Pharm 1994;51:1184-92.
10. Mosdell KW, Visconti JA. Emerging indications for octreotide therapy. 2. Am J Hosp Pharm 1994;51:1317-30.
11. Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 1994;69:173-80.
12. Mannucci PM, Altieri D, Faioni E. Vasopressin analogues. Their role in disorders of hemostasis. Ann NY Acad Sci 1987;509: 71-81.
13. Eberst ME, Berkowitz LR. Hemostasis in renal disease: pathophysiology and management. Am J Med 1994;96:168-79.
14. Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980;303:1318-22.
15. Seth S, Geier TM. Use of conjugated estrogens to control gastrointestinal bleeding in two patients with chronic renal failure. Clin Pharm 1988;7:906-9.
16. Escolar G, Cases A, Montageagudo J, et al. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med 1989;114:36-42.
17. Grosman I, Simon D. Potential uses of somatostatin and its synthetic analogue octreotide. Am J Gastroenterol 1990;85(9):1061-72.
18. Jenkins SA, Taylor BA, Nott DM, Ellenbogen S, Haggie J, Shields R. Management of massive upper gastrointestinal haemorrhage from multiple sites of peptic ulceration with somatostatin and octreotide - a report of five cases. Gut 1992;33:404-7.
19. Magnusson I, Ihre T, Johansson C, Seligson U, Torngren S, Uvnas-Moberg K. Randomised double blind trial of somatostatin in the treatment of massive upper gastrointestinal haemorrhage. Gut 1985;26:221-6.
20. Koch HJ, Escher GC, Lewis JS. Hormonal management of hereditary hemorrhagic telangiectasia. JAMA 1952;149: 1376-80.
21. Flessa HC, Glueck HI. Hereditary telangiectasia (Osler-Weber-Rendu disease). Arch Otolaryngol 1977;103:148-51.
22. Vase P, Lorentzen M. Histological findings following oestrogen treatment of hereditary haemorrhagic telangiectasia; a controlled double-blind investigation. J Laryngol Otol 1983;97:427-9.
23. McGee RR. Estrogen-progesterone therapy for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. South Med J 1979;72:1503.
24. Harrison DFN. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope 1982;92:314-20.
25. Liu YK, Kosfeld RE, Marcum SG. Treatment of uremic bleeding with conjugated oestrogen. Lancet 1984;2:887-90.
26. Livio M, Mannucci PM, Vigano G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N EnglJ Med 1986;315:731-5.
27. Bronner MH, Pate MB, Cunningham JT, Marsh WH. Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasia in chronic renal failure; an uncontrolled trial. Ann Intern Med 1986;105:371-4.
28. Shemin D, Elnour M, Amarantes B, Abuelo JG, Chazan JA. Oral estrogens decrease bleeding time and improve clinical bleeding in patients with renal failure. Am J Med 1990;89: 436-40.
29. Vigano G, Zoja C, Corna D, et al. 17-β-Estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanism. J Pharmacol Exp Ther 1990;252:344-8.
30. Sloand JA, Schiff MJ. Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia. Am J Kidney Dis 1995;26:22-6.
31. Zoja C, Noris M, Corna D, et al. L-Arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. Lab Invest 1991;65:479-83.
32. Sloand JA. Long-term therapy for uremic bleeding. Int J Artif Organs 1996;19:439-40.
33. Vigano G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G. Dose-effect and pharmacokinetics of estrogens given to correct bleeding times in uremia. Kidney Int 1988;34:853-8.